First Quadrant’s Aratana Therapeutics, Inc. PETX Stock Holding History

First Quadrant’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4	Closed	–	–	976
2017 Q4	$0	Buy	+4	New	+$24	﹤0.01%	1005

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

First Quadrant's PETX Position: Q1 2018 in Review

First Quadrant sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2018, closing a stake of 4 shares.

First Quadrant first reported a position in PETX in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 103 funds tracked by Wall St. Rank hold PETX as of Q1 2018.

First Quadrant reported no remaining Aratana Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
First Quadrant sold 4 Aratana Therapeutics, Inc. shares in Q1 2018.
First Quadrant first reported a position in Aratana Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
First Quadrant's Aratana Therapeutics, Inc. position peaked at $0 in Q4 2017.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2018.

Based on First Quadrant's 13F filing for Q1 2018, filed 20 Apr 2018.